[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] TRAYES K P,COKENAKES S E H.Breast cancer treatment[J].Am Fam Physician,2021,104(2):171-178.
[3] TUNGSUKRUTHAI S,PETPIROON N,CHANVORACHOTE P.Molecular mechanisms of breast cancer metastasis and potential anti-metastatic compounds[J].Anticancer Res,2018,38(5):2607-2618.
[4] MALEKI Z,NADELLA A,NADELLA M,et al.INSM1,a novel biomarker for detection of neuroendocrine neoplasms:cytopathologists' view[J].Diagnostics(Basel),2021,11(12):2172.
[5] GOTO Y,DE SILVA M G,TOSCANI A,et al.A novel human insulinoma-associated cDNA,IA-1,encodes a protein with "zinc-finger" DNA-binding motifs[J].J Biol Chem,1992,267(21):15252-15257.
[6] CHEN C,NOTKINS A L,LAN M S.Insulinoma-associated-1:from neuroendocrine tumor marker to cancer therapeutics[J].Mol Cancer Res,2019,17(8):1597-1604.
[7] KRIEGSMANN K,ZGORZELSKI C,KAZDAL D,et al.Insulinoma-associated protein 1(INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin,chromogranin A,and CD56[J].Appl Immunohistochem Mol Morphol,2020,28(3):237-242.
[8] MUKHOPADHYAY S,DERMAWAN J K,LANIGAN C P,et al.Insulinoma-associated protein 1(INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms:an immunohistochemical study of 345 cases,including 292 whole-tissue sections[J].Mod Pathol,2019,32(1):100-109.
[9] KAWASAKI T,KAIRA K.Insulinoma-associated protein 1(INSM1) expression in breast carcinomas with neuroendocrine morphologies:application and future prospective[J].Virchows Arch,2021,479(1):191-194.
[10] METOVIC J,CASTELLANO I,MARINELLI E,et al.INSM1 expression in breast neoplasms with neuroedocrinefeatures[J].Endocr Pathol,2021,32(4):452-460.
[11] TAO W,MA J,ZHENG J,et al.Silencing SCAMP1-TV2 inhibited the malignant biological behaviors of breast cancer cells by interaction with PUM2 to facilitate INSM1 mRNAdegradation[J].Front Oncol,2020,10:613.
[12] SHAW G,KAMEN R.A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation[J].Cell,1986,46(5):659-667.
[13] ZILFOU J T,HOFFMAN W H,SANK M,et al.The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation[J].Mol Cell Biol,2001,21(12):3974-3985.
[14] BRESLIN M B,ZHU M,NOTKINS A L,et al.Neuroendocrine differentiation factor,IA-1,is a transcriptional repressor and contains a specific DNA-binding domain:identification of consensus IA-1 binding sequence[J].Nucleic Acids Res,2002,30(4):1038-1045.
[15] LAN M S,BRESLIN M B.Structure,expression,and biological function of INSM1 transcription factor in neuroendocrine differentiation[J].FASEB J,2009,23(7):2024-2033.
[16] SEOK J Y,KANG M,DE PERALTA-VENTURINA M,et al.Diagnostic utility of INSM1 in medullary thyroid carcinoma[J].Int J Surg Pathol,2021,29(6):615-626.
[17] KUJI S,WATANABE R,SATO Y,et al.A new marker,insulinoma-associated protein 1(INSM1),for high-grade neuroendocrine carcinoma of the uterine cervix:analysis of 37 cases[J].Gynecol Oncol,2017,144(2):384-390.
[18] ROOPER L M,BISHOP J A,WESTRA W H.INSM1 is a sensitive and specific marker of neuroendocrine differentiation in head and neck tumors[J].Am J Surg Pathol,2018,42(5):665-671.
[19] SAKAKIBARA R,KOBAYASHI M,TAKAHASHI N,et al.Insulinoma-associated protein 1(INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A,synaptophysin,and CD56[J].Am J Surg Pathol,2020,44(6):757-764.
[20] TSAI H K,HORNICK J L,VIVERO M.INSM1 expression in a subset of thoracic malignancies and small round cell tumors:rare potential pitfalls for small cell carcinoma[J].Mod Pathol,2020,33(8):1571-1580.
[21] VISWANATHAN K,SIDDIQUI M T,BORCZUK A C.Insulinoma-associated protein 1 is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens[J].J Am Soc Cytopathol,2019,8(6):299-308.
[22] TANIGAWA M,NAKAYAMA M,TAIRA T,et al.Insulinoma-associated protein 1(INSM1) is a useful marker for pancreatic neuroendocrine tumor[J].Med Mol Morphol,2018,51(1):32-40.
[23] GONZÁLEZ I,LU H C,SNINSKY J,et al.Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts[J].Histopathology,2019,75(4):568-577.
[24] XIN Z,ZHANG Y,JIANG Z,et al.Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate[J].Hum Pathol,2018,79:151-159.
[25] RUSH P S,ROSENBAUM J N,ROY M,et al.Insulinoma-associated 1:a novel nuclear marker in Merkel cell carcinoma(cutaneous neuroendocrine carcinoma)[J].J Cutan Pathol,2018,45(2):129-135.
[26] ROTHROCK A T,STEWART J,3RD,LI F,et al.Exploration of INSM1 and hASH1 as additional markers in lung cytology samples of high-grade neuroendocrine carcinoma with indeterminate neuroendocrine differentiation[J].Diagn Cytopathol,2022,50(5):230-234.
[27] XU X,WANG G,DUAN Y,et al.Prognostic value and non-neuroendocrine role of INSM1 in small cell lung cancer[J].Pathol Res Pract,2022,229:153693.
[28] STAAF J,TRAN L,SÖDERLUND L,et al.Diagnostic value of insulinoma-associated protein 1(INSM1) and comparison with established neuroendocrine markers in pulmonary cancers[J].Arch Pathol Lab Med,2020,144(9):1075-1085.
[29] 杨文涛.关于WHO乳腺肿瘤分类第五版的解读[J].中华医学信息导报,2020,35(13):6.
[30] TAN P H,ELLIS I,ALLISON K,et al.The 2019 World Health Organization classification of tumours of the breast[J].Histopathology,2020,77(2):181-185.
[31] BUSSOLATI G,GUGLIOTTA P,SAPINO A,et al.Chromogranin-reactive endocrine cells in argyrophilic carcinomas ("carcinoids") and normal tissue of the breast[J].Am J Pathol,1985,120(2):186-192.
[32] ROSEN L E,GATTUSO P.Neuroendocrine tumors of the breast[J].Arch Pathol Lab Med,2017,141(11):1577-1581.
[33] MIURA K,NASU H,OGURA H.Double neuroendocrine ductal carcinomas in situ coexisting with a background of diffuse idiopathic neuroendocrine cell hyperplasia of breast:a case report and hypothesis of neuroendocrine tumor development[J].Pathol Int,2012,62(5):331-334.
[34] ROY M,BUEHLER D G,ZHANG R,et al.Expression of insulinoma-associated protein 1(INSM1) and orthopediahomeobox (OTP) in tumors with neuroendocrine differentiation at rare sites[J].Endocr Pathol,2019,30(1):35-42.
[35] TURKEVI-NAGY S,BÁTHORI Á,BÖCZ J,et al.Syntaxin-1 and insulinoma-associated protein 1 expression in breast neoplasms with neuroendocrine features[J].Pathol Oncol Res,2021,27:1610039.
[36] RAZVI H,TSANG J Y,POON I K,et al.INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer[J].Pathology,2021,53(2):170-178.
[37] KUDO N,TAKANO J,KUDOH S,et al.INSM1 immunostaining in solid papillary carcinoma of the breast[J].Pathol Int,2021,71(1):51-59.
[38] CLOYD J M,YANG R L,ALLISON K H,et al.Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast[J].Breast Cancer Res Treat,2014,148(3):637-644.
[39] PARK Y M,WU Y,WEI W,et al.Primary neuroendocrine carcinoma of the breast:clinical,imaging,and histologic features[J].AJR Am J Roentgenol,2014,203(2):W221-W230.
[40] TANG F,WEI B,TIAN Z,et al.Invasive mammary carcinoma with neuroendocrine differentiation:histological features and diagnostic challenges[J].Histopathology,2011,59(1):106-115.
[41] WEI B,DING T,XING Y,et al.Invasive neuroendocrine carcinoma of the breast:a distinctive subtype of aggressive mammary carcinoma[J].Cancer,2010,116(19):4463-4473.
[42] ZHU Y,LI Q,GAO J,et al.Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy[J].Breast J,2013,19(4):382-387.
[43] YIN L,DUAN J J,BIAN X W,et al.Triple-negative breast cancer molecular subtyping and treatment progress[J].Breast Cancer Res,2020,22(1):61.
[44] NOGUCHI M,INOKUCHI M,NOGUCHI M,et al.Axillary surgery for breast cancer:past,present,and future[J].Breast Cancer,2021,28(1):9-15.
[45] ZHANG Z,ZHANG Y,SUN X.Therapeutic options for contralateral axillary lymph node metastasis in breast cancer[J].Curr Probl Cancer,2021,45(5):100706.
[46] SHEYU L,HUI L,JUNYU Z,et al.Promoter methylation assay of SASH1 gene in breast cancer[J].J Buon,2013,18(4):891-898.
[47] CHEN C,BRESLIN M B,LAN M S.INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma[J].Oncotarget,2015,6(34):36700-36712.
[48] HSIEH A L,WALTON Z E,ALTMAN B J,et al.MYC and metabolism on the path to cancer[J].Semin Cell Dev Biol,2015,43:11-21.
[49] LOURENCO C,RESETCA D,REDEL C,et al.MYC protein interactors in gene transcription and cancer[J].Nat Rev Cancer,2021,21(9):579-591.
[50] CHEN C,BRESLIN M B,LAN M S.Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer[J].Cell Signal,2018,46:83-91. |
